News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ligand Pharmaceuticals Inc. (LGND) Enters into Agreement with Proximagen Neuroscience plc (PRX.L) for CXCR4 Target


9/17/2010 7:03:56 AM

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced today that it has transferred exclusive license rights to Proximagen Limited (AIM: PRX) for a series of compound hits related to the CXCR4 target with application for a number of indications including those related to the central nervous system. Ligand will receive an upfront payment and continue to be entitled to receive potential future milestone and royalty payments.

Read at Yahoo Finance
Read at Market Watch
Read at Earthtimes
Read at CNBC


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES